Status:
COMPLETED
Antihypertensive Response to Losartan and Genetic Polymorphisms
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hypertension
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the antihypertensive response of treatment with losartan with reference to genetic polymorphisms.
Eligibility Criteria
Inclusion
- Both gender less than 60 years old, with mild-moderate hypertension (SBP greater than and DBP equal or greater than 90 mmhg, BP \< 180/110)
- Never treated for hypertension or who have taken antihypertensive agents sporadically (not more than 15 days total therapy) but not in the 30 days prior to the first visit
- Patient in therapeutic wash out for 6 months
- Patient is asymptomatic, absence of significant concomitant diseases, except for non-familial hypercholesterolemia, absence of systemic diseases
- Women with menopause not treated with hormone replacement therapy or women of reproductive age who do not make use of estro-progestagen agents but who use another safe contraceptive method
- BMI \< 30 for men and \< 28 for women
Exclusion
- Secondary or malignant hypertension, Na \<130 mmol/l, K \>5,5 mmol/l, or \< 3,0 mmol/l
- Cardiac disease such as ischemic, HF, arrhythmia, cardiac surgery
- Pregnant, breast feeding
- History of nephropathy, metabolic disease, liver disease
- Alcohol or drug abuse
- History of angioedema
- Has a known hypersensibility to study drug(s)
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT00617877
Start Date
March 1 2005
End Date
June 1 2009
Last Update
July 22 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.